These three exemplary managers have widened their firms' economic moats and created real value for shareholders over the years.
The slow-recovering employment market will need a boost from housing construction and a realignment of worker skill sets to get back to full health, say Morningstar's Bob Johnson and Vishnu Lekraj.
Blockbuster sales and takeover potential create an attractive risk/reward tradeoff for this speculative biotech.
Regulatory issues that we believe have little impact on Novo Nordisk's long-run prospects have finally helped shares of the leading insulin maker go on sale.
©2014 Morningstar Advisor. All right reserved.